Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share. ChemoCentryx developed the drug TAVNEOS to treat ANCA-associated vasculitis. Sales of the drug in the U.S. in the first quarter of 2022, the first full quarter of sales, were $5.4 million. TAVNEOS is also already approved in major markets outside the U.S., including the European Union and Japan.